作者:Anna M. Jansson、Anna Więckowska、Christofer Björkelid、Samir Yahiaoui、Sanjeewani Sooriyaarachchi、Martin Lindh、Terese Bergfors、Shyamraj Dharavath、Matthieu Desroses、Surisetti Suresh、Mounir Andaloussi、Rautela Nikhil、Sharma Sreevalli、Bachally R. Srinivasa、Mats Larhed、T. Alwyn Jones、Anders Karlén、Sherry L. Mowbray
DOI:10.1021/jm4006498
日期:2013.8.8
including Mycobacterium tuberculosis and apicomplexan parasites, and differs from the classical mevalonate pathway that is essential in humans. Using a structure-based approach, we designed a number of analogues of fosmidomycin, including a series that are substituted in both the Cα and the hydroxamate positions. The latter proved to be a stable framework for the design of inhibitors that extend from the
抗疟药磷酰胺霉素靶向DXR,该酶催化MEP途径中第一个关键步骤,产生必需的类异戊二烯前体,异戊烯基二磷酸酯和二甲基烯丙基二磷酸酯。MEP途径被多种病原体所利用,包括结核分枝杆菌和apicomplexan寄生虫,并且不同于人类必需的经典甲羟戊酸途径。使用基于结构的方法,我们设计了许多磷酰胺霉素类似物,包括在Cα和异羟肟酸酯位置上均被取代的一系列类似物。事实证明,后者是设计抑制剂的稳定框架,该抑制剂从极性和局促的(因此不易药物化)底物结合位点延伸,并且可以首次桥接底物和辅因子结合位点。就在体外试验中杀死恶性疟原虫而言,许多这类化合物比磷霉素更有效。最好的IC 50为40 nM。